Penumbra Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Penumbra stock.
View analyst ratings for Penumbra or view top-rated stocks.

Wall Street analysts have given Penumbra a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Penumbra wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Penumbra is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Penumbra.

Penumbra, Inc. (NYSE:PEN) released its earnings results on Monday, August, 9th. The company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.02. The firm earned $184.26 million during the quarter, compared to analyst estimates of $170.77 million. Penumbra had a trailing twelve-month return on equity of 5.52% and a net margin of 2.37%. The firm's quarterly revenue was up 75.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) earnings per share.
View Penumbra's earnings history.

Penumbra's stock was trading at $176.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PEN shares have increased by 64.7% and is now trading at $291.24.
View which stocks have been most impacted by COVID-19.

Penumbra updated its FY 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $720 million-$730 million, compared to the consensus revenue estimate of $702.42 million.

6 brokers have issued twelve-month price targets for Penumbra's stock. Their forecasts range from $270.00 to $350.00. On average, they anticipate Penumbra's stock price to reach $324.86 in the next twelve months. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for Penumbra or view top-rated stocks among Wall Street analysts.

57 employees have rated Penumbra CEO Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among Penumbra's employees.

Some companies that are related to Penumbra include ResMed (RMD), Baxter International (BAX), Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), NovoCure (NVCR), Hill-Rom (HRC), Globus Medical (GMED), ShockWave Medical (SWAV), Tandem Diabetes Care (TNDM), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI) and Nevro (NVRO).
View all of PEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), The Boeing (BA) and DexCom (DXCM).

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Penumbra's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.96%), Vanguard Group Inc. (8.87%), BlackRock Inc. (8.75%), Baillie Gifford & Co. (3.67%), Price T Rowe Associates Inc. MD (3.43%) and Clearbridge Investments LLC (2.81%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder.
View institutional ownership trends for Penumbra.

PEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Morgan Stanley, William Blair Investment Management LLC, Franklin Resources Inc., Marshall Wace LLP, Marshall Wace LLP, and Price T Rowe Associates Inc. MD. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, and Thomas Wilder.
View insider buying and selling activity for Penumbra or view top insider-selling stocks.

PEN stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Amundi, State Street Corp, First Trust Advisors LP, Neuberger Berman Group LLC, PFM Health Sciences LP, Baillie Gifford & Co., and Balyasny Asset Management LLC.
View insider buying and selling activity for Penumbra or or view top insider-buying stocks.

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PEN stock can currently be purchased for approximately $291.24.

Penumbra has a market capitalization of $10.65 billion and generates $560.41 million in revenue each year. The company earns $-15,700,000.00 in net income (profit) each year or $0.11 on an earnings per share basis.

Penumbra employs 3,300 workers across the globe.

The official website for Penumbra is www.penumbrainc.com.

Penumbra is headquartered at One Penumbra Place, Alameda CA, 94502.

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at (510) 748-3200 or via email at [email protected]